Compare ADV & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADV | AUPH |
|---|---|---|
| Founded | 1987 | 1993 |
| Country | United States | Canada |
| Employees | 73000 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 438.2M | 2.0B |
| IPO Year | N/A | 2014 |
| Metric | ADV | AUPH |
|---|---|---|
| Price | $35.11 | $15.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $45.83 | $17.25 |
| AVG Volume (30 Days) | 67.7K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | $0.63 | $17.54 |
| Revenue Next Year | $0.45 | $15.74 |
| P/E Ratio | ★ N/A | $64.08 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $0.49 | $7.29 |
| 52 Week High | $46.80 | $16.88 |
| Indicator | ADV | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 54.75 | 52.83 |
| Support Level | $1.00 | $14.28 |
| Resistance Level | $46.80 | $16.38 |
| Average True Range (ATR) | 3.94 | 0.68 |
| MACD | -1.28 | -0.03 |
| Stochastic Oscillator | 12.48 | 63.10 |
Advantage Solutions Inc provides outsourced sales, marketing, merchandising, sampling, and retailer support services to consumer packaged goods manufacturers and retailers across North America. Its services are designed to support distribution, retail execution, shopper engagement, and private brand development across both physical and digital commerce environments. The company serves various clients across grocery, mass, club, retail pharmacy, convenience, and other channels. It operates through three reportable segments: Branded Services, Experiential Services, and Retailer Services. The majority of the revenue is derived from the Experiential Services segment, which provides in-store and digital sampling programs, demonstrations, and experiential events for manufacturers and retailers.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.